blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3034076

EP3034076 - COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  06.08.2021
Database last updated on 12.07.2024
FormerThe patent has been granted
Status updated on  28.08.2020
FormerGrant of patent is intended
Status updated on  23.03.2020
FormerExamination is in progress
Status updated on  14.07.2017
Most recent event   Tooltip14.06.2024Lapse of the patent in a contracting state
New state(s): TR		published on 17.07.2024 [2024/29]
Applicant(s)For all designated states
JC (Wuxi) COMPANY, Inc.
No. 200, 5th District, Science and Technology Park
7 Changjiang Road
New District
Wuxi 214028, JS / CN
[2016/25]
Inventor(s)01 / CHENG, Jingcai
No.200 Floor 2
5th District
Building A
Science and Technology Park, 7 Changjiang Road, Wuxi New District
Wuxi Jiangsu 214028 / CN
02 / ZHANG, Chunxia
No.200 Floor 2
5th District
Building A
Science and Technology Park, 7 Changjiang Road, Wuxi New District
Wuxi Jiangsu 214028 / CN
03 / CHENG, Zhiwei
No.200 Floor 2
5th District
Building A
Science and Technology Park, 7 Changjiang Road, Wuxi New District
Wuxi Jiangsu 214028 / CN
 [2016/25]
Representative(s)Cabinet Laurent & Charras
Le Contemporain
50 Chemin de la Bruyère
69574 Dardilly Cedex / FR
[2016/25]
Application number, filing date14836229.613.08.2014
[2016/25]
WO2014CN84324
Priority number, dateCN20131035241413.08.2013         Original published format: CN201310352414
CN20131036410120.08.2013         Original published format: CN201310364101
CN20141034641918.07.2014         Original published format: CN201410346419
[2016/25]
Filing languageZH
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2015021929
Date:19.02.2015
Language:ZH
[2015/07]
Type: A1 Application with search report 
No.:EP3034076
Date:22.06.2016
Language:EN
[2016/25]
Type: B1 Patent specification 
No.:EP3034076
Date:30.09.2020
Language:EN
[2020/40]
Search report(s)International search report - published on:CN19.02.2015
(Supplementary) European search report - dispatched on:EP20.09.2016
ClassificationIPC:A61K31/26, A61P35/00, A61K45/06
[2016/34]
CPC:
A61K31/26 (EP,US); A61K31/16 (EP,US); A61K31/165 (EP,US);
A61K31/167 (EP,US); A61K31/17 (EP,US); A61K31/282 (EP,US);
A61K31/33 (EP,US); A61K31/337 (EP,US); A61K31/4164 (EP,US);
A61K31/4166 (EP,US); A61K31/4184 (EP,US); A61K31/436 (EP,US);
A61K31/437 (EP,US); A61K31/44 (EP,US); A61K31/4412 (EP,US);
A61K31/4439 (EP,US); A61K31/4745 (EP,US); A61K31/475 (EP,US);
A61K31/4985 (EP,US); A61K31/506 (EP,US); A61K31/517 (EP,US);
A61K31/519 (EP,US); A61K31/58 (EP,US); A61K31/69 (EP,US);
A61K31/704 (EP,US); A61K31/7068 (EP,US); A61K31/7076 (EP,US);
A61K33/243 (EP,US); A61K33/36 (EP,US); A61K38/10 (EP,US);
A61K38/14 (EP,US); A61P1/04 (EP); A61P1/16 (EP);
A61P1/18 (EP); A61P11/00 (EP); A61P13/08 (EP);
A61P13/10 (EP); A61P13/12 (EP); A61P15/00 (EP);
A61P17/00 (EP); A61P19/00 (EP); A61P25/00 (EP);
A61P35/00 (EP); A61P35/02 (EP); A61P43/00 (EP) (-)
C-Set:
A61K31/165, A61K2300/00 (US,EP);
A61K31/16, A61K2300/00 (EP,US);
A61K31/26, A61K2300/00 (US,EP);
A61K31/436, A61K2300/00 (US,EP);
A61K31/44, A61K2300/00 (US,EP);
A61K31/475, A61K2300/00 (EP,US);
A61K31/4985, A61K2300/00 (US,EP);
A61K31/506, A61K2300/00 (EP,US);
A61K31/517, A61K2300/00 (EP,US);
A61K31/58, A61K2300/00 (US,EP);
A61K31/69, A61K2300/00 (EP,US)
(-)
Former IPC [2016/25]A61K31/26, A61P35/00
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2016/25]
Extension statesBANot yet paid
MENot yet paid
TitleGerman:KOMBINIERTE ANWENDUNG EINER ISOTHIOCYANATVERBINDUNG UND EINER KREBSBEKÄMPFENDEN MEDIZIN[2016/25]
English:COMBINED APPLICATION OF ISOTHIOCYANATE COMPOUND AND ANTI-CANCER MEDICINE[2016/25]
French:UTILISATION COMBINÉE D'UN MÉDICAMENT ANTI-CANCÉREUX ET D'UN COMPOSÉ DE LA CLASSE DES ISOTHIOCYANATES[2016/25]
Entry into regional phase11.03.2016Translation filed 
11.03.2016National basic fee paid 
11.03.2016Search fee paid 
11.03.2016Designation fee(s) paid 
11.03.2016Examination fee paid 
Examination procedure11.03.2016Examination requested  [2016/25]
07.04.2017Amendment by applicant (claims and/or description)
12.07.2017Despatch of a communication from the examining division (Time limit: M04)
21.11.2017Reply to a communication from the examining division
27.03.2018Despatch of a communication from the examining division (Time limit: M04)
06.08.2018Reply to a communication from the examining division
17.12.2018Despatch of a communication from the examining division (Time limit: M04)
17.04.2019Reply to a communication from the examining division
27.08.2019Despatch of a communication from the examining division (Time limit: M02)
25.10.2019Reply to a communication from the examining division
24.03.2020Communication of intention to grant the patent
28.07.2020Fee for grant paid
28.07.2020Fee for publishing/printing paid
28.07.2020Receipt of the translation of the claim(s)
Opposition(s)01.07.2021No opposition filed within time limit [2021/36]
Fees paidRenewal fee
31.08.2016Renewal fee patent year 03
22.08.2017Renewal fee patent year 04
28.08.2018Renewal fee patent year 05
26.08.2019Renewal fee patent year 06
20.08.2020Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Lapses during opposition  TooltipHU13.08.2014
AL30.09.2020
AT30.09.2020
CY30.09.2020
CZ30.09.2020
DK30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
MK30.09.2020
NL30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SE30.09.2020
SI30.09.2020
SK30.09.2020
SM30.09.2020
TR30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
[2024/29]
Former [2024/22]HU13.08.2014
AL30.09.2020
AT30.09.2020
CY30.09.2020
CZ30.09.2020
DK30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
MK30.09.2020
NL30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SE30.09.2020
SI30.09.2020
SK30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
Former [2023/37]HU13.08.2014
AL30.09.2020
AT30.09.2020
CY30.09.2020
CZ30.09.2020
DK30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
NL30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SE30.09.2020
SI30.09.2020
SK30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
Former [2023/30]HU13.08.2014
AL30.09.2020
AT30.09.2020
CY30.09.2020
CZ30.09.2020
DK30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
NL30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SE30.09.2020
SK30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
Former [2023/29]HU13.08.2014
AL30.09.2020
AT30.09.2020
CZ30.09.2020
DK30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
NL30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SE30.09.2020
SK30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
Former [2022/18]AL30.09.2020
AT30.09.2020
CZ30.09.2020
DK30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
MC30.09.2020
NL30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SE30.09.2020
SK30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
Former [2021/48]AL30.09.2020
AT30.09.2020
CZ30.09.2020
DK30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
IT30.09.2020
LT30.09.2020
LV30.09.2020
NL30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SE30.09.2020
SK30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
Former [2021/37]AL30.09.2020
AT30.09.2020
CZ30.09.2020
DK30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
NL30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SE30.09.2020
SK30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
Former [2021/28]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
NL30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SE30.09.2020
SK30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
Former [2021/25]AL30.09.2020
AT30.09.2020
CZ30.09.2020
EE30.09.2020
ES30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
NL30.09.2020
PL30.09.2020
RO30.09.2020
RS30.09.2020
SE30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
IS30.01.2021
PT01.02.2021
Former [2021/23]AT30.09.2020
CZ30.09.2020
EE30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
NL30.09.2020
RO30.09.2020
RS30.09.2020
SE30.09.2020
SM30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
PT01.02.2021
Former [2021/22]CZ30.09.2020
EE30.09.2020
FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
NL30.09.2020
RO30.09.2020
RS30.09.2020
SE30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
PT01.02.2021
Former [2021/21]FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
NL30.09.2020
RS30.09.2020
SE30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
PT01.02.2021
Former [2021/20]FI30.09.2020
HR30.09.2020
LT30.09.2020
LV30.09.2020
RS30.09.2020
SE30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
Former [2021/10]FI30.09.2020
HR30.09.2020
LV30.09.2020
RS30.09.2020
SE30.09.2020
BG30.12.2020
NO30.12.2020
GR31.12.2020
Former [2021/08]FI30.09.2020
SE30.09.2020
BG30.12.2020
NO30.12.2020
Former [2021/07]FI30.09.2020
NO30.12.2020
Documents cited:Search[X]EP1564305  (INST CURIE [FR], et al) [X] 1-14 * page 4; claims 9-10 *;
 [X]US2008124407  (EATON DAVID L [US], et al) [X] 1-14 * paragraph [0062]; claim 11 *;
 [A]US2009005438  (CHENG JINGCAI [CN], et al) [A] 1-14 * paragraphs [0014] , [0 42] *;
 [X]WO2009108755  (WYETH CORP [US], et al) [X] 1-14 * page 4; claim 3 *;
 [X]WO2009108857  (COMBITHERA INC [US], et al) [X] 1-14 * claim 39 *;
 [X]WO2010065329  (UNIV TEXAS [US], et al) [X] 1-14 * paragraphs [0009] , [0019] - [0020] - [0088] *;
 [X]US2013079401  (CHEN YU-JEN [TW], et al) [X] 1-14 * paragraph [0039]; claim - *;
 [X]  - WANG X ET AL, "ENHANCED CYTOTOXICITY OF MITOMYCIN C IN HUMAN TUMOUR CELLS WITH INDUCERS OF DT-DIAPHORASE", BRITISH JOURNAL OF CANCER, NATURE PUBLISHING GROUP, GB, (19900601), vol. 80, no. 8, doi:10.1038/SJ.BJC.6690489, ISSN 0007-0920, pages 1223 - 1230, XP008017449 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1038/sj.bjc.6690489
 [X]  - Elaine Tseng ET AL, "Effect of Organic Isothiocyanates on the P-Glycoprotein- and MRP1-Mediated Transport of Daunomycin and Vinblastine", Pharmaceutical Research, New York, doi:10.1023/A:1020460700877, (20021001), pages 1509 - 1515, URL: http://rd.springer.com/article/10.1023%2FA%3A1020460700877, XP055288446 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1023/A:1020460700877
 [X]  - YAN JI ET AL, "Effect of Organic Isothiocyanates on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, (20041201), vol. 21, no. 12, doi:10.1007/S11095-004-7679-1, ISSN 1573-904X, pages 2261 - 2269, XP019370667 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1007/s11095-004-7679-1
 [X]  - SUTAPA MUKHERJEE ET AL, "Isothiocyanates sensitize the effect of chemotherapeutic drugs via modulation of protein kinase C and telomerase in cervical cancer cells", MOLECULAR AND CELLULAR BIOCHEMISTRY, KLUWER ACADEMIC PUBLISHERS, BO, (20090412), vol. 330, no. 1-2, doi:10.1007/S11010-009-0095-4, ISSN 1573-4919, pages 9 - 22, XP019772739 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1007/s11010-009-0095-4
 [X]  - D. TRACHOOTHAM ET AL, "Effective elimination of fludarabine-resistant CLL cells by PEITC through a redox-mediated mechanism", BLOOD, US, (20080901), vol. 112, no. 5, doi:10.1182/blood-2008-04-149815, ISSN 0006-4971, pages 1912 - 1922, XP055288453 [X] 1-14 * page 1918 *

DOI:   http://dx.doi.org/10.1182/blood-2008-04-149815
 [X]  - GEORGIOS KALLIFATIDIS ET AL, "Sulforaphane Increases Drug-mediated Cytotoxicity Toward Cancer Stem-like Cells of Pancreas and Prostate", MOLECULAR THERAPY, GB, (20101012), vol. 19, no. 1, doi:10.1038/mt.2010.216, ISSN 1525-0016, pages 188 - 195, XP055288280 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1038/mt.2010.216
 [X]  - BETTINA M. KAMINSKI ET AL, "Sulforaphane potentiates oxaliplatin-induced cell growth inhibition in colorectal cancer cells via induction of different modes of cell death", CANCER CHEMOTHERAPY AND PHARMACOLOGY., BERLIN., (20100806), vol. 67, no. 5, doi:10.1007/s00280-010-1413-y, ISSN 0344-5704, pages 1167 - 1178, XP055288458 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1007/s00280-010-1413-y
 [X]  - XIANTAO WANG ET AL, "Phenethyl isothiocyanate sensitizes human cervical cancer cells to apoptosis induced by cisplatin", MOLECULAR NUTRITION & FOOD RESEARCH, (20110519), vol. 55, no. 10, doi:10.1002/mnfr.201000560, ISSN 1613-4125, pages 1572 - 1581, XP055161158 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1002/mnfr.201000560
 [X]  - KATHERINE LIU ET AL, "Synergistic effect of paclitaxel and epigenetic agent phenethyl isothiocyanate on growth inhibition, cell cycle arrest and apoptosis in breast cancer cells", CANCER CELL INTERNATIONAL, BIOMED CENTRAL, LONDON, GB, (20130207), vol. 13, no. 1, doi:10.1186/1475-2867-13-10, ISSN 1475-2867, page 10, XP021145453 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1186/1475-2867-13-10
 [X]  - AAMER QAZI ET AL, "Anticancer Activity of a Broccoli Derivative, Sulforaphane, in Barrett Adenocarcinoma: Potential Use in Chemoprevention and as Adjuvant in Chemotherapy", TRANSLATIONAL ONCOLOGY, United States, (20101201), vol. 3, no. 6, doi:10.1593/tlo.10235, ISSN 1936-5233, pages 389 - 399, XP055288539 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1593/tlo.10235
 [X]  - Suppipat, "Targeting AKT Signaling in Pediatric Acute Lymphoblastic Leukemia with Sulforaphane | Blood Journal", Blood 2011 118:1521, (20110101), URL: http://www.bloodjournal.org/content/118/21/1521, (20160714), XP055288536 [X] 1-14 * abstract *
 [X]  - DONG XIAO ET AL, "Phenethyl Isothiocyanate Sensitizes Androgen-Independent Human Prostate Cancer Cells to Docetaxel-Induced Apoptosis In Vitro and In Vivo", PHARMACEUTICAL RESEARCH, KLUWER ACADEMIC PUBLISHERS-PLENUM PUBLISHERS, NL, (20100225), vol. 27, no. 4, doi:10.1007/S11095-010-0079-9, ISSN 1573-904X, pages 722 - 731, XP019793962 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1007/s11095-010-0079-9
 [XP]  - ANNA MINARINI ET AL, "Exploring the effects of isothiocyanates on chemotherapeutic drugs", EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, GB, (20131003), vol. 10, no. 1, doi:10.1517/17425255.2013.843668, ISSN 1742-5255, pages 25 - 38, XP055288278 [XP] 1-14 * table 1 *

DOI:   http://dx.doi.org/10.1517/17425255.2013.843668
 [A]  - V. RAUSCH ET AL, "Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics", CANCER RESEARCH, (20100608), vol. 70, no. 12, doi:10.1158/0008-5472.CAN-10-0066, ISSN 0008-5472, pages 5004 - 5013, XP055022831 [A] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-10-0066
 [X]  - LI-CHING LIN ET AL, "Sulforaphane Potentiates the Efficacy of Imatinib against Chronic Leukemia Cancer Stem Cells through Enhanced Abrogation of Wnt/[beta]-Catenin Function", JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY, US, (20120718), vol. 60, no. 28, doi:10.1021/jf301981n, ISSN 0021-8561, pages 7031 - 7039, XP055300713 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1021/jf301981n
 [X]  - DOUDICAN N A ET AL, "Enhancement of arsenic trioxide cytotoxicity by dietary isothiocyanates in human leukemic cells via a reactive oxygen species-dependent mechanism", LEUKEMIA RESEARCH, NEW YORK,NY, US, vol. 34, no. 2, doi:10.1016/J.LEUKRES.2009.05.017, ISSN 0145-2126, (20100201), pages 229 - 234, (20090621), XP026915688 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1016/j.leukres.2009.05.017
 [X]  - Y. HU ET AL, "Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound -phenylethyl isothiocyanate", BLOOD, US, (20101014), vol. 116, no. 15, doi:10.1182/blood-2009-11-256354, ISSN 0006-4971, pages 2732 - 2741, XP055288476 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.1182/blood-2009-11-256354
 [X]  - Marianna Halasi ET AL, "TUMORIGENESIS AND NEOPLASTIC PROGRESSION Combination of Oxidative Stress and FOXM1 Inhibitors Induces Apoptosis in Cancer Cells and Inhibits Xenograft Tumor Growth From the Departments of Medicine* and Biochemistry and Molecular Genetics", Am J Pathol, (20130101), pages 257 - 265, URL: http://ac.els-cdn.com/S0002944013002691/1-s2.0-S0002944013002691-main.pdf?_tid=cd7e5c10-74f4-11e6-9f77-00000aab0f26&acdnat=1473250725_1e1440be1abd78ef90649ed94a8647a4, XP055300636 [X] 1-14 * abstract *
 [X]  - HERR, "Dietary polyphenol quercetin targets pancreatic cancer stem cells", INTERNATIONAL JOURNAL OF ONCOLOGY, GR, (20100721), vol. 37, no. 3, doi:10.3892/ijo_00000704, ISSN 1019-6439, XP055300640 [X] 1-14 * abstract *

DOI:   http://dx.doi.org/10.3892/ijo_00000704
 [X]  - Jakubikova, "Sulforaphane and PEITC Augment Activity of Conventional and Novel Anti-Myeloma Drugs", Blood, 112(11) 916, (20081116), URL: http://www.bloodjournal.org/content/112/11/2648, (20160908), XP055300830 [X] 1-14 * abstract *
 [X]  - DANIEL K CHAN ET AL, "Metformin and phenethyl isothiocyanate combined treatment in vitro is cytotoxic to ovarian cancer cultures", JOURNAL OF OVARIAN RESEARCH, BIOMED CENTRAL LTD, LONDON, UK, (20120710), vol. 5, no. 1, doi:10.1186/1757-2215-5-19, ISSN 1757-2215, page 19, XP021117288 [X] 1-4,6-14 * abstract *

DOI:   http://dx.doi.org/10.1186/1757-2215-5-19
International search[X]CN101167741  (BEIJING TUBERCULOSIS AND THORA [CN]);
 [X]  - DONG, XIAO ET AL., "Phenethyl Isothiocyanate Sensitizes Androgen-Independent Human Prostate Cancer Cells to Docetaxel-Induced Apoptosis In Vitro and In Vivo", PHARMACEUTICAL RESEARCH, (20101231), vol. 4, no. 27, pages 722 - 731, XP019793962

DOI:   http://dx.doi.org/10.1007/s11095-010-0079-9
 [X]  - VANESSA RAUSCH ET AL., "Synergistic Activity of Sorafenib and Sulforaphane Abolishes Pancreatic Cancer Stem Cell Characteristics", CANCER RESEARCH, (20101231), vol. 12, no. 70, pages 5004 - 5013, XP055022831

DOI:   http://dx.doi.org/10.1158/0008-5472.CAN-10-0066
Examination   - Arif Hussain ET AL, "Concurrent Sulforaphane and Eugenol Induces Differential Effects on Human Cervical Cancer Cells", INTEGRATIVE CANCER THERAPIES, US, (20110307), vol. 11, no. 2, doi:10.1177/1534735411400313, ISSN 1534-7354, pages 154 - 165, XP055461799

DOI:   http://dx.doi.org/10.1177/1534735411400313
    - LIDIA SLIWKA ET AL, "The Comparison of MTT and CVS Assays for the Assessment of Anticancer Agent Interactions", PLOS ONE, (20160519), vol. 11, no. 5, doi:10.1371/journal.pone.0155772, page e0155772, XP055461801

DOI:   http://dx.doi.org/10.1371/journal.pone.0155772
    - Gerlinde Pappa ET AL, "Quantitative combination effects between sulforaphane and 3,3'-diindolylmethane on proliferation of human colon cancer cells in vitro", CARCINOGENESIS., GB, (20070701), vol. 28, no. 7, doi:10.1093/carcin/bgm044, ISSN 0143-3334, pages 1471 - 1477, XP055461802

DOI:   http://dx.doi.org/10.1093/carcin/bgm044
by applicantCA2630262
 US8039511
 US8410170
 JP5308160B
 CN20051040865
 EP20060817815
 CN20091052231
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.